Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter‐alpha‐trypsin inhibitor and saposin <scp>B</scp> but increased expression of an inter‐alpha‐trypsin inhibitor heavy chain 4 fragment

Jayapalan, Jaime Jacqueline; Ng, Keng L.; Shuib, Adawiyah Suriza; Razack, Azad Hassan Abdul; Hashim, Onn Haji

doi:10.1002/elps.201200583

Cited by 26 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated levels of ITIH4-derived peptides have been observed in serum of breast cancer patients [54]. Increased levels of ITIH4 fragments have also been found in urine of early prostate cancer patients [55]. Reduced levels of ITIH4-derived peptides have also been observed in urine of ovarian cancer patients [56].…”

Section: Resultsmentioning

confidence: 99%

Identification of differentially expressed serum proteins in gastric adenocarcinoma

Subbannayya

Mir

Renuse

et al. 2015

Journal of Proteomics

View full text Add to dashboard Cite

Gastric adenocarcinoma is an aggressive cancer with poor prognosis. Blood based biomarkers of gastric cancer have the potential to improve diagnosis and monitoring of these tumors. Proteins that show altered levels in the circulation of gastric cancer patients could prove useful as putative biomarkers. We used an iTRAQ-based quantitative proteomic approach to identify proteins that show altered levels in the sera of patients with gastric cancer. Our study resulted in identification of 643 proteins, of which 48 proteins showed increased levels and 11 proteins showed decreased levels in serum from gastric cancer patients compared to age and sex matched healthy controls. Proteins that showed increased expression in gastric cancer included inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4), Mannose-binding protein C (MBL2), sex hormone-binding globulin (SHBG), insulin-like growth factor-binding protein 2 (IGFBP2), serum amyloid A protein (SAA1), Orosomucoid 1 (ORM1) and extracellular superoxide dismutase [Cu–Zn] (SOD3). We used multiple reaction monitoring assays and validated elevated levels of ITIH4 and SAA1 proteins in serum from gastric cancer patients. Biological significance Gastric cancer is a highly aggressive cancer associated with high mortality. Serum-based biomarkers are of considerable interest in diagnosis and monitoring of various diseases including cancers. Gastric cancer is often diagnosed at advanced stages resulting in poor prognosis and high mortality. Pathological diagnosis using biopsy specimens remains the gold standard for diagnosis of gastric cancer. Serum-based biomarkers are of considerable importance as they are minimally invasive. In this study, we carried out quantitative proteomic profiling of serum from gastric cancer patients to identify proteins that show altered levels in gastric cancer patients. We identified more than 50 proteins that showed altered levels in gastric cancer patient sera. Validation in a large cohort of well classified patient samples would prove useful in identifying novel blood based biomarkers for gastric cancers. This article is part of a Special Issue entitled: Proteomics in India.

show abstract

Section: Resultsmentioning

confidence: 99%

Identification of differentially expressed serum proteins in gastric adenocarcinoma

Subbannayya

Mir

Renuse

et al. 2015

Journal of Proteomics

View full text Add to dashboard Cite

show abstract

“…There are a few reports that proposed this protein as an OC marker [37, 42]. Changes in the levels of ITIH4-derived peptides were also observed in urine of early prostate cancer patients [43] and in the serum of breast cancer patients [44] and gastric adenocarcinoma patients [41]. A correlation was also suggested between different fragmentation of ITIH4 and disease conditions [45].…”

Section: Discussionmentioning

confidence: 99%

MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer

et al. 2017

View full text Add to dashboard Cite

BackgroundDue to high mortality and lack of efficient screening, new tools for ovarian cancer (OC) diagnosis are urgently needed. To broaden the knowledge on the pathological processes that occur during ovarian cancer tumorigenesis, protein-peptide profiling was proposed.MethodsSerum proteomic patterns in samples from OC patients were obtained using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF). Eighty nine serum samples (44 ovarian cancer and 45 healthy controls) were pretreated using solid-phase extraction method. Next, a classification model with the most discriminative factors was identified using chemometric algorithms. Finally, the results were verified by external validation on an independent test set of samples.ResultsMain outcome of this study was an identification of potential OC biomarkers by applying liquid chromatography coupled with tandem mass spectrometry. Application of this novel strategy enabled the identification of four potential OC serum biomarkers (complement C3, kininogen-1, inter-alpha-trypsin inhibitor heavy chain H4, and transthyretin). The role of these proteins was discussed in relation to OC pathomechanism.ConclusionsThe study results may contribute to the development of clinically useful multi-component diagnostic tools in OC. In addition, identifying a novel panel of discriminative proteins could provide a new insight into complex signaling and functional networks associated with this multifactorial disease.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3467-2) contains supplementary material, which is available to authorized users.

show abstract

“…Protein AMBP, secreted by kidneys and gallbladder, has also been found in studies analyzing blood [77,81] and urine [97]. Other acute response proteins such as SERPINA1, TTR and ITIH4 have also been suggested as candidate biomarkers in serum [78] and urine [97,98].…”

Section: Reproducibility and Specificity Of The Biomarkers Discoveredmentioning

confidence: 90%

“…Nine proteins with differential abundances were acute phase response proteins and the expression pattern of 4 differed from the defined expression in the canonical pathway. Worth mentioning is that among these proteins was inter-alpha-trypsin inhibitor (ITIH4) which already was reported to be up-regulated in the urine of PCa patients in the study of Jayapalan et al, [98]. The urine levels of TF, AMPB and HP were validated and the expression level was confirmed by immunoturbidimetry.…”

Section: Urine Biomarkersmentioning

confidence: 91%

Proteomics in Diagnosis of Prostate Cancer/ Протеомика Во Дијагноза На Простатниот Карцином

Davalieva

Polenakovič

2015

Prilozi

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most frequently diagnosed malignancy in men worldwide. The introduction of prostate specific antigen (PSA) has greatly increased the number of men diagnosed with PCa but at the same time, as a result of the low specificity, led to overdiagnosis, resulting to unnecessary biopsies and high medical cost treatments. The primary goal in PCa research today is to find a biomarker or biomarker set for clear and effecttive diagnosis of PCa as well as for distinction between aggressive and indolent cancers. Different proteomic technologies such as 2-D PAGE, 2-D DIGE, MALDI MS profiling, shotgun proteomics with label-based (ICAT, iTRAQ) and label-free (SWATH) quantification, MudPIT, CE-MS have been applied to the study of PCa in the past 15 years. Various biological samples, including tumor tissue, serum, plasma, urine, seminal plasma, prostatic secretions and prostatic-derived exosomes were analyzed with the aim of identifying diagnostic and prognostic biomarkers and developing a deeper understanding of the disease at the molecular level. This review is focused on the overall analysis of expression proteomics studies in the PCa field investigating all types of human samples in the search for diagnostics biomarkers. Emphasis is given on proteomics platforms used in biomarker discovery and characterization, explored sources for PCa biomarkers, proposed candidate biomarkers by comparative proteomics studies and the possible future clinical application of those candidate biomarkers in PCa screening and diagnosis. In addition, we review the specificity of the putative markers and existing challenges in the proteomics research of PCa.

show abstract

Urine of patients with early prostate cancer contains lower levels of light chain fragments of inter‐alpha‐trypsin inhibitor and saposin B but increased expression of an inter‐alpha‐trypsin inhibitor heavy chain 4 fragment

Cited by 26 publications

References 31 publications

Identification of differentially expressed serum proteins in gastric adenocarcinoma

Identification of differentially expressed serum proteins in gastric adenocarcinoma

MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer

Proteomics in Diagnosis of Prostate Cancer/ Протеомика Во Дијагноза На Простатниот Карцином

Contact Info

Product

Resources

About